AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33504555 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (dinutuximab + GM-CSF + IL2)
Number of subjects: 226
Study 33504555 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin only
Number of subjects: 226
Study 35432566 — intervention group
Group type: EXPERIMENTAL
Intervention: ZuoJin Pill (ZJP)
Number of subjects: 68
Study 35432566 — intervention group
Group type: COMPARATOR
Intervention: Marzulene-S granule
Number of subjects: 68
Study 33405304 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care with motivational interviewing (CCMI)
Number of subjects: 100
Study 33405304 — intervention group
Group type: COMPARATOR
Intervention: Attention control psychoeducation (ACP)
Number of subjects: 100
Study 34422864 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led pain management program
Number of subjects: 262
Study 34422864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 262
Study 33303110 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes of treadmill walking (60-70% heart rate max)
Number of subjects: 116
Study 33303110 — intervention group
Group type: COMPARATOR
Intervention: Restful reading (non-exercise control)
Number of subjects: 116
Study 35858941 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded spurs and posterior build-ups
Number of subjects: 49
Study 35858941 — intervention group
Group type: COMPARATOR
Intervention: Bonded spurs alone
Number of subjects: 49
Study 35858941 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 49
Study 34032040 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking plate external fixation
Number of subjects: 92
Study 34032040 — intervention group
Group type: COMPARATOR
Intervention: Traditional open reduction with plate internal fixation
Number of subjects: 92
Study 36341753 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive treatment (systolic blood pressure target <120 mm Hg)
Number of subjects: 821
Study 36341753 — intervention group
Group type: COMPARATOR
Intervention: Less intensive treatment (systolic blood pressure target 140-180 mm Hg)
Number of subjects: 821
Study 32205376 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan-based personal lubricant (self-applied anal microbicide gel)
Number of subjects: 380
Study 32205376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (self-applied placebo gel)
Number of subjects: 380
Study 35834200 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-interest prompt
Number of subjects: 591
Study 35834200 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial prompt
Number of subjects: 591
Study 33372717 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-delivered school mental health intervention
Number of subjects: 0
Study 33372717 — intervention group
Group type: COMPARATOR
Intervention: Implementation science framework
Number of subjects: 0
Study 35351805 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL menthol e-cigarettes
Number of subjects: 64
Study 35351805 — intervention group
Group type: COMPARATOR
Intervention: non-menthol e-cigarettes
Number of subjects: 64
Study 35351805 — intervention group
Group type: EXPERIMENTAL
Intervention: menthol e-cigarettes
Number of subjects: 64
Study 33761083 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) sessions delivered by social insurance caseworkers
Number of subjects: 0
Study 33761083 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) sessions
Number of subjects: 0
Study 34993863 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis App (mobile application delivering interactive video education on viral hepatitis in English, Cantonese, Mandarin, or Vietnamese, along with Provider Alert and Provider Panel Notification)
Number of subjects: 452
Study 34993863 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (mobile application delivering nutrition and physical activity education and Provider Panel Notification)
Number of subjects: 452
Study 34054112 — intervention group
Group type: EXPERIMENTAL
Intervention: lumateperone 42 mg
Number of subjects: 1073
Study 34054112 — intervention group
Group type: COMPARATOR
Intervention: risperidone 4 mg
Number of subjects: 1073
Study 34054112 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1073
Study 32492181 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental analogues depicting completed or potential sexual assault in various formats (written, audio, video, virtual simulation)
Number of subjects: 17
Study 32492181 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental analogues
Number of subjects: 17
Study 35349526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (30 minutes using a cycle ergometer)
Number of subjects: 20
Study 35349526 — intervention group
Group type: COMPARATOR
Intervention: Routine HD without exercise (control)
Number of subjects: 20
Study 34108140 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximate WBC DNA methylation in ERCC1
Number of subjects: 594
Study 34108140 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant WBC DNA methylation in ERCC1
Number of subjects: 594
Study 35995953 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 471
Study 35995953 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 471
Study 32505126 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 58
Study 32505126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 32324634 — intervention group
Group type: EXPERIMENTAL
Intervention: Improv course (15-hour course to teach interprofessional empathy)
Number of subjects: 86
Study 32324634 — intervention group
Group type: EXPERIMENTAL
Intervention: Improv course
Number of subjects: 86
Study 35770246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 59
Study 35770246 — intervention group
Group type: COMPARATOR
Intervention: Sudarshan Kriya Yoga (SKY)
Number of subjects: 59
Study 32222767 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 86
Study 32222767 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 86
Study 35807783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (50,000 IU on the first and eighth days)
Number of subjects: 129
Study 35807783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 IU)
Number of subjects: 129
Study 35807783 — intervention group
Group type: COMPARATOR
Intervention: No cholecalciferol supplementation (Control Group)
Number of subjects: 129
Study 35357058 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride (100 mg t.i.d.)
Number of subjects: 100
Study 35357058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35357058 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride in overlapping PDS/EPS subgroup (n = 55)
Number of subjects: 100
Study 35357058 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride in pure PDS subgroup (n = 45)
Number of subjects: 100
Study 33212341 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk powder (WMP)
Number of subjects: 3
Study 33212341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfat dry milk (NFDM)
Number of subjects: 3
Study 33212341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrated powders
Number of subjects: 3
Study 33212341 — intervention group
Group type: EXPERIMENTAL
Intervention: NFDM and WMP
Number of subjects: 3
Study 33212341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrated NFDM and WMP
Number of subjects: 3
Study 35967112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 867
Study 35967112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 867
Study 34615779 — intervention group
Group type: EXPERIMENTAL
Intervention: TurmNova® lozenges containing turmeric extract 100 mg and clove oil 10 mg three times daily for 3 months
Number of subjects: 80
Study 34615779 — intervention group
Group type: COMPARATOR
Intervention: Intralesional infiltration of 2 mL dexamethasone (4 mg/mL) + hyaluronidase 1500 IU dissolved in 0.5 mL of 2% lignocaine twice a week for 3 months
Number of subjects: 80
Study 32978121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (LI)
Number of subjects: 208
Study 32978121 — intervention group
Group type: COMPARATOR
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 208
Study 34755569 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (4 sessions on days 1/2/4/6 for 1 week)
Number of subjects: 30
Study 34755569 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacotherapy for pain management without acupuncture)
Number of subjects: 30
Study 34933975 — intervention group
Group type: EXPERIMENTAL
Intervention: We Care Solar Suitcase (solar electric system providing lighting and power)
Number of subjects: 30
Study 34933975 — intervention group
Group type: COMPARATOR
Intervention: Control group (before intervention)
Number of subjects: 30
Study 34933975 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention
Number of subjects: 30
Study 35400227 — intervention group
Group type: EXPERIMENTAL
Intervention: Burpee Interval Training (BIT)
Number of subjects: 18
Study 35400227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 18
Study 35400227 — intervention group
Group type: COMPARATOR
Intervention: Vigorous Intensity Continuous Training (VICT)
Number of subjects: 18
Study 35973185 — intervention group
Group type: EXPERIMENTAL
Intervention: High total/low simple carbohydrate diet for 9 weeks
Number of subjects: 98
Study 35973185 — intervention group
Group type: COMPARATOR
Intervention: High total/high simple carbohydrate diet (control group)
Number of subjects: 98
Study 35973185 — intervention group
Group type: EXPERIMENTAL
Intervention: All carbohydrate modification groups
Number of subjects: 98
Study 35973185 — intervention group
Group type: EXPERIMENTAL
Intervention: High total/low simple carbohydrate diet
Number of subjects: 98
Study 35005793 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 U/min oxytocin
Number of subjects: 124
Study 35005793 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 U/min oxytocin
Number of subjects: 124
Study 35005793 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.24 U/min oxytocin
Number of subjects: 124
Study 35005793 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.36 U/min oxytocin
Number of subjects: 124
Study 33302751 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulants
Number of subjects: 7642
Study 33829609 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib and carotuximab (TRC105) combination therapy
Number of subjects: 150
Study 33829609 — intervention group
Group type: COMPARATOR
Intervention: Axitinib monotherapy
Number of subjects: 150
Study 33056965 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinalamin treatment course every 6 months
Number of subjects: 147
Study 33056965 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study 35345524 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education combined with personalized psychological nursing intervention
Number of subjects: 170
Study 35345524 — intervention group
Group type: COMPARATOR
Intervention: Routine education and routine examination (Control)
Number of subjects: 170
Study 33762716 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional sequence of epirubicin/cyclophosphamide and docetaxel
Number of subjects: 311
Study 33762716 — intervention group
Group type: COMPARATOR
Intervention: Reverse sequence of epirubicin/cyclophosphamide and docetaxel
Number of subjects: 311
Study 33138109 — intervention group
Group type: COMPARATOR
Intervention: ILCOR
Number of subjects: 286
Study 33138109 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR
Number of subjects: 286
Study 33138109 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnsberg
Number of subjects: 286
Study 36653090 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor (evolocumab) 140 mg subcutaneous injection
Number of subjects: 60
Study 36653090 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor (evolocumab)
Number of subjects: 60
Study 36653090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32354299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subacromial corticosteroid injection
Number of subjects: 30
Study 32354299 — intervention group
Group type: COMPARATOR
Intervention: Blind subacromial corticosteroid injection
Number of subjects: 30
Study 32354299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ultrasound and Blind)
Number of subjects: 30
Study 32992440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g·kg·FFM−1 GLN (HIGH)
Number of subjects: 14
Study 32992440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g·kg·FFM−1 GLN (MED)
Number of subjects: 14
Study 32992440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g·kg·FFM−1 GLN (LOW)
Number of subjects: 14
Study 32992440 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 14
Study 35337288 — intervention group
Group type: COMPARATOR
Intervention: Bilateral tDCS
Number of subjects: 48
Study 35337288 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 48
Study 36126132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SeQuent SCB, 4 μg/mm²)
Number of subjects: 101
Study 36126132 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon (SeQuent Please, 3 μg/mm²)
Number of subjects: 101
Study 36126132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SCB and PCB
Number of subjects: 101
Study 35545431 — intervention group
Group type: EXPERIMENTAL
Intervention: Within Our Reach curriculum (12 hours)
Number of subjects: 1418
Study 35545431 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 1418
Study 33710659 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐to‐home cognitive‐behavioral therapy
Number of subjects: 90
Study 33710659 — intervention group
Group type: COMPARATOR
Intervention: Clinic‐based treatment as usual
Number of subjects: 90
Study 32603554 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG4-related sclerosing cholangitis (IgG4-SC) patients
Number of subjects: 1045
Study 35799473 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 172
Study 33600846 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 136
Study 33600846 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 136
Study 33600846 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 136
Study 34985003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable-polymer sirolimus-eluting Orsiro stent (O-SES)
Number of subjects: 80
Study 34985003 — intervention group
Group type: COMPARATOR
Intervention: Polymer-free biolimus-A9-eluting BioFreedom stent (BF-BES)
Number of subjects: 80
Study 33728806 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized prediction model for COVID-19 deterioration
Number of subjects: 276
Study 32538762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine and ropivacaine infiltration anesthesia
Number of subjects: 92
Study 35110636 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume Continuous Exercise (CE)
Number of subjects: 20
Study 35110636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-volume Intermittent exercise of Long bouts with Long interval (ILL)
Number of subjects: 20
Study 35110636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-volume Intermittent exercise of Long bouts with Short interval (ILS)
Number of subjects: 20
Study 35110636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-volume Intermittent exercise of Short bouts with Short interval (ISS)
Number of subjects: 20
Study 35110636 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 20
Study 34003285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy+ (CFT+) with psychologist support and option of additional usual care
Number of subjects: 176
Study 34003285 — intervention group
Group type: COMPARATOR
Intervention: Interdisciplinary pain management pathway (usual care)
Number of subjects: 176
Study 36700035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain, orally administrated at 1.0×10^10 colony-forming units once daily for 10 days
Number of subjects: 60
Study 36700035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34107173 — intervention group
Group type: EXPERIMENTAL
Intervention: Flonoxin 400 mg
Number of subjects: 30
Study 34107173 — intervention group
Group type: COMPARATOR
Intervention: Avelox 400 mg
Number of subjects: 30
Study 35805767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental care, anticipatory guidance on oral health and dietary intake, motivational interviewing
Number of subjects: 0
Study 35805767 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for participant engagement
Number of subjects: 0
Study 34657222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampreloxetine 5 mg and 10 mg
Number of subjects: 34
Study 34657222 — intervention group
Group type: COMPARATOR
Intervention: Ampreloxetine (median dose 15 mg)
Number of subjects: 34
Study 34657222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 34657222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampreloxetine (median dose 10 mg)
Number of subjects: 34
Study 34657222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampreloxetine
Number of subjects: 34
Study 34657222 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal after ampreloxetine treatment
Number of subjects: 34
Study 34051103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided SGB
Number of subjects: 10
Study 34051103 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic guided SGB
Number of subjects: 10
Study 35685430 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 50
Study 35685430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33290938 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative exposure therapy for forensic offender rehabilitation (FORNET)
Number of subjects: 27
Study 33290938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 27
Study 33290938 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 27
Study 34800568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 38
Study 34800568 — intervention group
Group type: COMPARATOR
Intervention: Unstructured Psychotherapy (Talking Control: TC)
Number of subjects: 38
Study 32066559 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 110
Study 32066559 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery (CPS)
Number of subjects: 110
Study 35916246 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 97
Study 35916246 — intervention group
Group type: COMPARATOR
Intervention: Online training
Number of subjects: 97
Study 32488320 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review process using a web-based checklist with nine rating categories and dichotomous response format (deficiency/no deficiency)
Number of subjects: 30
Study 32488320 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality rating of medical reports
Number of subjects: 30
Study 32271840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortetropin®
Number of subjects: 100
Study 32271840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32271840 — intervention group
Group type: COMPARATOR
Intervention: Fortetropin® vs Placebo
Number of subjects: 100
Study 35325298 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc-C
Number of subjects: 120
Study 35325298 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 120
Study 33610175 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 1% at 30 mg
Number of subjects: 45
Study 33610175 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 1% at 40 mg
Number of subjects: 45
Study 33610175 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 1% at 50 mg
Number of subjects: 45
Study 32662036 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of bisphosphonates
Number of subjects: 140202
Study 32662036 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent use of bisphosphonates
Number of subjects: 140202
Study 32662036 — intervention group
Group type: EXPERIMENTAL
Intervention: Past use of bisphosphonates
Number of subjects: 140202
Study 32662036 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment duration less than 1 year
Number of subjects: 140202
Study 32662036 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment duration more than 1 year
Number of subjects: 140202
Study 32662036 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified analysis by age, sex, and background cardiovascular risk
Number of subjects: 140202
Study 36058419 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (0.8ng/kg, intravenously) + MP (40mg, orally)
Number of subjects: 8
Study 36058419 — intervention group
Group type: COMPARATOR
Intervention: PBO + MP (40mg, orally)
Number of subjects: 8
Study 33459805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 323
Study 33459805 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 323
Study 33459805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with vertebral fractures
Number of subjects: 323
Study 35627702 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention (n = 73)
Number of subjects: 458
Study 35627702 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 458